Rachel M Layman, MD

Peer-Reviewed Articles

1. Ha MH, Raghavedra AS, Kettner NM, Damodaran S, Layman RM, Hunt KK, Shen U, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients as compared to endocrine therapy alone in the second line setting - A large institutional study. Int J Cancer 150(12):2025-37, 2022. e-Pub 2022. PMID: 35133007.
2. Patt D, Liu X, Li B, McRoy L,Layman RM, Brufsky A. Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. Clin Breast Cancer. e-Pub 2022.
3. Layman RM, Lin H, Gutierrez Barrera AM, Karaturi MS, Yam C, Arun BK. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer. Cancer Med 11(6):1474-1483, 2022. e-Pub 2022. PMID: 35128817.
4. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Correction to: Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol 16(6):865, 2021. PMID: 34652714.
5. Brufsky A, Liu X, Li B, McRoy L, Layman RM. Real-world tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol 16:601-611, 2021. e-Pub 2021. PMID: 34338965.
6. Jhaveri K , Juric D, Yap YS, Cresta S, Layman RM, Duhoux FP, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor-positive breast cancer. Clin Can Res 27(21):5760-5770, 2021. PMID: 34433648.
7. Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy. Ann Oncol 32(5):642-51, 2021. e-Pub 2021. PMID: 33617937.
8. DeMichele, A, Cristofanilli, M, Brufsky, A, Liu X, Mardekian J, McRoy L, Layman RM, Emir B, Torres MA, Rugo HS, Finn RS. Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast Cancer Res 23(1):37, 2021. PMID: 33761995.
9. Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelrahim M, Diab A, Yee C, Abdelwahab N. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10(1), 2021. PMID: 33643693.
10. Layman, RM, Arun B. PARP inhibitors in triple-negative breast cancer including those with BRCA mutations. Cancer J 27(1):67-75, 2021. PMID: 33475295.
11. Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest New Drugs 38(5):1400-1410, 2020. e-Pub 2020. PMID: 31953695.
12. Wesolowski R, Stover DG, Lustberg MB, Shoben A, Zhao M, Mrozek E, Layman RM, Macrae E, Duan W, Zhang J, Hall N, Wright CL, Gillespie S, Berger M, Chalmers JJ, Carey A, Balasubramanian P, Miller BL, Amaya P, Andreopoulou E, Sparano J, Shapiro CL, Villalona-Calero MA, Geyer S, Chen A, Grever MR, Knopp MV, Ramaswamy B. Phase I study of veliparib on an intermittent and continuous schedule in combination with carboplatin in metastatic breast cancer: a safety and [18F]-fluorothymidine positron emission tomography biomarker study. Oncologist 25(8):e1158-e1169, 2020. e-Pub 2020. PMID: 32452601.
13. Bayraktar S, Zhou JZ, Bassett R, Gutierrez Barrera AM, Layman RM, Valero V, Arun B. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J 26(8):1572-1582, 2020. e-Pub 2020. PMID: 32497289.
14. Lau R, Du L, Chen E, Fu C, Gould R, Marczyk M, Sinn BV, Layman R, Bedrosian I, Valero V, Symmans WF. Technical validity of a customized assay of sensitivity to endocrine therapy using sections from fixed breast cancer tissue. Clin Chem 66(7):934-45, 2020. PMID: 32613237.
15. Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans W. SET ER/PR: A robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer 5(16), 2019. PMID: 31231679.
16. Lustberg MB, Orchard TS, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro CL, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Res Treat 167(3):709-718, 2018. e-Pub 2017. PMID: 29101597.
17. Makary MS, Lionberg A, Khayat M, Lustberg MB, AlTaani J, Pan XJ, Layman RR, Raman SV, Layman RM, Dowell JD. Advanced stage breast cancer is associated with catheter-tip thrombus formation following implantable central venous port placement. Phlebology:268355518774442. e-Pub 2018. PMID: 29771187.
18. Wesolowski R, Duggan MC, Stiff A, Markowitz J, Trikha P, Levine KM, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae ER, Lustberg MB, Reinbolt RE, Mrozek E, Byrd JC, Caligiuri MA, Mace TA, Carson WE. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother 66(11):1437-1447, 2017. e-Pub 2017. PMID: 28688082.
19. Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K. Randomized phase II study of ramucirumab or icrucumab in combination with capecitabine in patients with previously treated locally advanced or metastatic breast cancer. Oncologist 22(3):245-254, 2017. e-Pub 2017. PMID: 28220020.
20. Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P. Clinical and translational results of a phase II, randomized trial of an anti-IGF-1R (Cixutumumab) in women with breast cancer that progressed on endocrine therapy. Clin Cancer Res 22(2):301-9, 2016. e-Pub 2015. PMID: 26324738.
21. Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Breast cancer risk reduction (Version 2.2015). J Natl Compr Canc Netw 13(7):880-915, 2015. PMID: 26150582.
22. Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support Care Cancer 23(7):2019-24, 2015. e-Pub 2014. PMID: 25519756.
23. Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials. Oncologist 20(4):337-43, 2015. e-Pub 2015. PMID: 25732265.
24. Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs 32(6):1285-94, 2014. e-Pub 2014. PMID: 24894652.
25. Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Clin Breast Cancer 14(4):228-34, 2014. e-Pub 2014. PMID: 24703985.
26. Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, Emery CF, Layman RM, Mrozek EE, Glaser R. Yoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol 32(10):1040-9, 2014. e-Pub 2014. PMID: 24470004.
27. Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res 16(2):R23, 2014. e-Pub 2014. PMID: 24602188.
28. Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 21(10):2679-86, 2013. e-Pub 2013. PMID: 23686402.
29. Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol 71(5):1183-90, 2013. e-Pub 2013. PMID: 23430121.
30. Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 19(6):1512-24, 2013. e-Pub 2013. PMID: 23340294.
31. Mrózek E, Layman R, Ramaswamy B, Schaaf L, Li X, Ottman S, Shapiro CL. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer. Clin Breast Cancer 12(2):151-6, 2012. PMID: 22444722.
32. Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 11(4):221-7, 2011. e-Pub 2011. PMID: 21729671.
33. Layman RM, Thomas DG, Griffith KA, Smerage JB, Helvie MA, Roubidoux MA, Diehl KM, Newman LA, Sabel MS, Hayman JA, Pierce LJ, Hayes DF, Schott AF. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 13(14):4092-7, 2007. PMID: 17634534.
34. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, Khan AP, Helvie M, Meyer CR, Chenevert TL, Rehemtulla A, Ross BD. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 13(2 Pt 1):443-50, 2007. PMID: 17255264.

Invited Articles

1. Layman RM, and Arun B. PARP inhibitors in triple negative breast cancer including those with BRCA mutations. The Cancer Journal 27(1):67-75, 2021. PMID: 33475295.
2. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in cancer therapy: Current evidence and future directions. Target Oncol 13(1):21-38, 2018. e-Pub 2017. PMID: 29218622.
3. Layman R, Olson K, Van Poznak C. Bisphosphonates for breast cancer: Questions answered, questions remaining. Hematol Oncol Clin North Am 21(2):341-67, 2007. PMID: 17512453.

Abstracts

1. Kalinsky K, Layman RM, Kaufman PA, Graff SL, Bianchini G, Martin M, Zhou Y, Knoderer H, Litchfield L, Wander SA. postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. 2022 ASCO Annual Meeting. Citation: J Clin Oncol 40(Supp 16), 2022.
2. Patt DA, Liu X, Li B, McRoy L, Layman RM, Brufsky A. Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer. 2021 ASCO Annual Meeting. Citation: J Clin Oncol 39(Suppl 15), 2021.
3. Hobbs E, Lindquist E, Sullivan B, Yoon E, Yuan Y, Marx A, Willey J, Sun H, Layman RM, Stover D, Yuan Y and Lim B. Neratinib and tepotinib combination in advanced breast cancer and inflammatory breast cancer patients with abnormal HER2 and c-Met pathway activity as measured by the CELsignia signaling pathway activity test. San Antonio Breast Cancer Symposium, 2020.
4. Rugo HS, Bardia A, Han H, Layman RM, Kern K, Dees E, Forero A, Pathan N, pierce KJ, Lu MJ, Wesolowski R, Kabos P, Houk B. Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy in women with estrogen receptor positive metastatic breast cancer. J Clin Oncol, 2020.
5. Wesolowski R, Pathan N, Zhu Z, Stringer-Reasor EM, Han HS, Dees EC, Bardia A, Layman RM, Weise A, Kabos P, Lu JM, Kern KA, Pierce KJ, and Rugo Hope. Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC). 2020 ASCO Virtual Scientific Program. Citation: J Clin Oncol 38(Suppl: abstr 1052), 2020.
6. Curigliano G, Cresta S, Yap YS, Juric D, Duhoux FP, Terret C, Takahashi S, Layman RM, Kundamal N, Baldon D, Liao S, Crystal AS, Jhaveri K. Phase I/Ib study of oral selective estrogen receptor degrader (SERD) in combination with Alpelisib (BYL719) in estrogen receptor-positive (ER+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) with progression on endocrine therapy (ET). San Antonio Breast Cancer Symposium, 2018.
7. Ramaswamy B, Zhang J, Hall N, Schregel K, Lustberg MB, Wesolowski R, Mrozek E, Layman RM, Olson EM, Ottman S, Camp A, Chalmers JJ, Geyer SM, Villalona-Calero MA, Shapiro CL, Grever MR, Knopp MV. NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer. ASCO Annual Meeting, 2013.
8. Ramaswamy B, Srividya V, Mullins DA, Carothers S, Young G, Wenrui D, Zhao W, Lustberg M, Leon M, Weslowski R, Layman R, Mrozek E, Shapiro CL, Villalona-CaleroM. Prevalence of dysfunctional fanconi anemia (FA) DNA repair pathway in breast cancer. Cancer Research 71(24), 2011.

Book Chapters

1. Saxena K, Layman RM. Systemic Therapy, Hormone Receptor Positive Breast Cancer. In: Cancer Medicine Holland/Frei Textbook. 10.